TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03531034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise Training
Description: The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
Study: NCT03053271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
Study: NCT01926665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
Study: NCT02008045

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.
Study: NCT03073967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: 100 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: 100 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: 100 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: 100 mg oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice
Description: Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
Study: NCT02009007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dopamine
Description: continuous infusion during operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: continuous infusion of phenylephrine during operation
Study: NCT01235429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partners in Care
Description: Diabetes self-management education
Study: NCT01738711

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
Study: NCT00562965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: intravenous rituximab at a dose of 375 mg/m2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone/prednisolone
Description: oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
Study: NCT05305027

Intervention type: BEHAVIORAL
Intervention: Prompt diagnois pregnancy outcome
Study: NCT00562965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: mitoxantrone 10 mg/m2 intravenous on day 2
Study: NCT02105766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant
Study: NCT00562965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: fludarabine 25 mg/m2 intravenous on days 2 through 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: oral dexamethasone 20 mg/day on days 1-5
Study: NCT04442854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
Study: NCT06128317

Intervention type: OTHER
Intervention: no intervention is intended.
Description: no intervention is intended.
Study: NCT02848235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care + EMMA
Description: Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
Study: NCT02202590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM Capsule
Description: Imaging of the esophagus using the SECM capsule and system
Study: NCT01447355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study: NCT01580527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Total parenteral nutrition in postoperative of pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Early enteral nutrition in postoperative of pancreaticoduodenectomy
Study: NCT01056211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: treatment without laser
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: treatment without laser
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: treatment without laser
Description: Starlux 300 Lux 1540nm Fractional laser hand piece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment
Description: Starlux 300 Lux 1540nm Fractional laser hand piece
Study: NCT03293719

Intervention type: DEVICE
Intervention: BPK-S Integration UC
Description: Primary Knee Endoprosthesis

Intervention type: DEVICE
Intervention: BPK-S Integration UC
Description: Primary Knee Endoprosthesis
Study: NCT03042442

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of care biomarkers
Description: Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of care biomarkers
Description: Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC

Intervention type: OTHER
Intervention: Clinical, venous blood samples, pancreatic tissue
Description: Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.

Intervention type: OTHER
Intervention: Clinical, venous blood samples, pancreatic tissue
Description: Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.

Intervention type: OTHER
Intervention: Follow-up
Description: Participants will be assessed (by telephone) over a period of 2 years

Intervention type: OTHER
Intervention: Follow-up
Description: Participants will be assessed (by telephone) over a period of 2 years
Study: NCT02034435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Salt diet plus Placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Salt diet plus Placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Salt diet plus Placebo tablet
Study: NCT02105766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Immunosuppressant
Study: NCT02034435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Salt diet plus Placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Sodium diet plus Salt tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Sodium diet plus Salt tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epleronone
Description: 50mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epleronone
Description: 50mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg daily
Study: NCT01539941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication integration protocol
Description: MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
Study: NCT03848312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 45 computerized sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: Participants will be completing a total of 45 computerized cognitive stimulation sessions.
Study: NCT02105766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Immunosuppressant and myelosuppressant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Immunosuppressant and myelosuppressant

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: mobilize peripheral blood stem cells for apheresis collection
Study: NCT04429243

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Stent Graft
Description: On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
Study: NCT03186898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy (Radiation Therapy)
Description: Undergo proton therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy (Radiation Therapy)
Description: Undergo photon therapy
Study: NCT04293354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Plane Block
Description: Serratus Plane Block was performed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No block was performed
Study: NCT01195220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV-T
Description: This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV-T
Description: This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV-Plus
Description: This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
Study: NCT01849458

Intervention type: DEVICE
Intervention: BioFiber
Description: Subjects implanted with BioFiber or BioFiber-CM Scaffold
Study: NCT00858416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kineticure System followed by sham
Description: 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham followed by Kineticure System
Description: sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
Study: NCT04989569

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
Study: NCT00942734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: One tablet (150 mg) by mouth every day of each 28 day study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 1 tablet (5 mg) by mouth every day of each 28 day study cycle.
Study: NCT02969707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro TMS system (MagVenture, Denmark)
Description: The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro TMS system (MagVenture, Denmark)
Description: The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hypnosis
Description: Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
Study: NCT04329975

Intervention type: DRUG
Intervention: Desmopressin
Description: Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
Study: NCT02438527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chart for CPR guidance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chart for CPR guidance
Study: NCT01082731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine- Artesunate
Description: Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
Study: NCT03522753

Intervention type: DEVICE
Group type: OTHER
Intervention: Metal skin staples
Description: Routine closure methods/material for surgical wounds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal skin staples
Description: Routine closure methods/material for surgical wounds

Intervention type: DEVICE
Group type: OTHER
Intervention: Nylon sutures
Description: Routine closure methods/material for surgical wounds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon sutures
Description: Routine closure methods/material for surgical wounds
Study: NCT02622750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: four-branched Dacron graft
Description: The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft.